CANbridge Pharmaceuticals Inc. (01228) reported an unchanged authorized share capital of USD 50,000 as of January 31, 2026. The total issued shares rose from 511,120,234 to 511,222,234, reflecting an increase of 102,000 shares primarily due to share option exercises under the company's Post-IPO Share Option Scheme. The exercise of options generated HKD 227,960 during the period. The company confirmed continued compliance with public float requirements mandated by the Hong Kong Stock Exchange.